GlassScriptPhysician profile
Erik Anthony Davis
NPI 1518226000
$12,132.43
in general payments reported to CMS, 2019-2025
41 companies · $2,446 in 2025
The $2,446 reported for 2025 was more than what 95% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,392 · 2020: $467 · 2021: $3,563 · 2022: $518 · 2023: $1,094 · 2024: $2,651 · 2025: $2,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,635 · Travel and Lodging: $1,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,634.57 |
| Travel and Lodging | $1,557.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,481.10 | 2019-2025 | Eterna, Proclaim, Penta |
| Stryker Corporation | $2,034.08 | 2023-2025 | Augment Injectable, Optablate, Omnicurve |
| Spinal Simplicity, LLC | $1,847.22 | 2021-2024 | Ha Minuteman G3-R |
| Collegium Pharmaceutical, INC. | $1,007.81 | 2019-2025 | Belbuca |
| Boston Scientific Corporation | $876.04 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Medtronic USA, INC. | $656.91 | 2019 | |
| Nevro Corp. | $525.51 | 2021-2024 | Senza |
| Medtronic, INC. | $436.29 | 2021-2025 | Inceptiv, Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Biotronik Nro, INC. | $312.41 | 2025 | Prospera |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.48 | 2019-2025 | Relistor |
| Globus Medical, INC. | $238.48 | 2025 | Senza, Vyrsa V1 |
| Ibsa Pharma INC. | $173.79 | 2021-2023 | Tirosint, Licart |
| Biodelivery Sciences International, INC. | $166.98 | 2019-2021 | |
| Si-Bone, INC. | $148.80 | 2020-2024 | |
| Scilex Pharmaceuticals INC. | $103.09 | 2019-2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $98.12 | 2024-2025 | Evoke |
| Stimwave Technologies Incorporated | $77.50 | 2022 | |
| Forte Bio-Pharma LLC | $77.07 | 2019-2020 | |
| Nalu Medical, INC. | $53.92 | 2023-2024 | Nalu Neurostimulation System |
| Pfizer INC. | $51.78 | 2019-2021 | |
| Ermi LLC | $44.79 | 2021 | |
| Arbor Pharmaceuticals, INC. | $38.34 | 2021 | |
| Convatec INC. | $33.06 | 2023 | |
| Virtus Pharmaceuticals LLC | $31.62 | 2023 | Levorphanol Tartrate |
| Painteq LLC | $30.31 | 2023 | Painteq |
| Horizon Therapeutics Plc | $30.15 | 2022 | |
| Bioventus LLC | $28.90 | 2025 | Durolane |
| Fidia Pharma USA INC. | $24.76 | 2019 | |
| Teleflex LLC | $22.62 | 2025 | Barrigel |
| Averitas Pharma INC. | $22.17 | 2023 | Qutenza |
| Trevena, INC. | $21.39 | 2022 | |
| Grt US Holding, INC. | $21.31 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $18.13 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.67 | 2019 | |
| Curonix LLC | $14.77 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Astrazeneca Pharmaceuticals LP | $13.46 | 2019 | |
| Kaleo, INC. | $12.47 | 2019 | |
| Baudax Bio INC. | $11.94 | 2021 | |
| Lilly USA, LLC | $11.84 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.54 | 2021 | |
| Zyla Life Sciences, INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.